CUE

Cue Biopharma Inc

• Benzinga·1d ago

  12 Health Care Stocks Moving In Friday's Intraday Session

• Seeking Alpha·09/21 21:14

  Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

• TipRanks·09/21 20:30

  B. Riley would be ‘aggressive buyers’ of Cue Biopharma after selloff

• Benzinga·09/21 17:06

  12 Health Care Stocks Moving In Monday's Intraday Session

• Seeking Alpha·09/21 15:20

  Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset

• Benzinga·09/21 14:45

  What's Going on With Cue Biopharma Stock on Monday?

• TipRanks·09/21 12:29

  Cue Biopharma reports positive Phase 2 CUE-221 data

• Benzinga·09/21 12:06

  12 Health Care Stocks Moving In Monday's Pre-Market Session

• Seeking Alpha·09/21 11:00

  At a glance: stocks gapping up premarket

• Dow Jones·09/21 10:59

  Cue Biopharma Shares Jump With Positive Results in Chronic Spontaneous Urticaria Trial

• Benzinga·09/21 09:01

  Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

• Benzinga·09/21 06:32

  Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis

• NASDAQ·09/20 18:37

  Cue Biopharma's CUE-221 Meets Phase 2 Goals In Chronic Hives Study; Stock Up

• TipRanks·09/20 14:15

  Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

• Seeking Alpha·09/18 15:28

  Cue Biopharma is a new Buy at B. Riley on valuation